Blood-based quantification of Aβ oligomers indicates impaired clearance from brain in ApoE ε4 positive subjects
Open Access
- 10 December 2024
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 4 (1) , 1-13
Abstract
Background: Quantification of Amyloid beta (Aβ) oligomers in plasma enables early diagnosis of Alzheimer’s Disease (AD) and improves our understanding of underlying pathologies. However, quantification necessitates an extremely sensitive and selective technology because of very low Aβ oligomer concentrations and possible interference from matrix components. Methods: In this report, we developed and validated a surface-based fluorescence distribution analysis (sFIDA) assay for quantification of Aβ oligomers in plasma. Results: The blood-based sFIDA assay delivers a sensitivity of 1.8 fM, an inter- and intra-assay variation below 20% for oligomer calibration standards and no interference with matrix components. Quantification of Aβ oligomers in 359 plasma samples from the DELCODE cohort reveals lower oligomer concentrations in subjective cognitive decline and AD patients than healthy Control participants. Conclusions: Correlation analysis between CSF and plasma oligomer concentrations indicates an impaired clearance of Aβ oligomers that is dependent on the ApoE ε4 status.Keywords
Funding Information
- Helmholtz Association (HVF0079)
This publication has 59 references indexed in Scilit:
- Correction to “Aβ oligomers peak in early stages of Alzheimer's disease preceding tau pathology”Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2024
- Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centersAlzheimer's & Dementia, 2022
- Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practiceAlzheimer's & Dementia, 2022
- An ultra‐sensitive immunoassay detects and quantifies soluble Aβ oligomers in human plasmaAlzheimer's & Dementia, 2021
- Safety and pharmacokinetics of the orally available antiprionic compound PRI‐002: A single and multiple ascending dose phase I studyAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2020
- Advancements of the sFIDA method for oligomer‐based diagnostics of neurodegenerative diseasesFEBS Letters, 2018
- Effect of sleep on overnight cerebrospinal fluid amyloid β kineticsAnnals of Neurology, 2017
- A Specific Enzyme-Linked Immunosorbent Assay for Measuring β-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer DiseaseArchives of Neurology, 2009
- Systematical evaluation of the effects of sample collection procedures on low‐molecular‐weight serum/plasma proteome profilingProteomics, 2006
- Amyloid-β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in PlasmaBiochemical and Biophysical Research Communications, 2000